Evoke Pharma Inc
EVOK evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Lead Asset:
- gimoti (Approved)
What it means
What to watch
Prepared research question
What matters most for EVOK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
gimoti (Approved)
Next Catalyst
—
Tracking 1 pipeline candidate for Evoke Pharma Inc.
Run Evoke Pharma Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evoke Pharma Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Evoke Pharma Inc's lead drug candidate?
Evoke Pharma Inc's most advanced tracked candidate is gimoti (Approved) for acute and recurrent diabetic gastroparesis.
Who is the CEO of Evoke Pharma Inc?
Solana Beach is the chief executive officer of Evoke Pharma Inc (EVOK).
What therapeutic areas does Evoke Pharma Inc focus on?
Evoke Pharma Inc develops therapies across Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.